Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

By J. Goldstein. British Journal of Clinical Pharmacology, 2001

675 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The CYP2C19 or “S-mephenytoin polymorphism” was discovered during the early 1980s and was since then established as one of the clinically most relevant P450 polymorphisms (Küpfer & Preisig, 1984; Wrighton et al., 1993; De Morais et al., 1994a; Meyer & Zanger, 1997; Goldstein, 2001; Rosemary & Aditha”
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction (2006, background): “In addition, the azole antifungal fluconazole [138], the 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors [139] and fluvastatin [139] are inhibitors of CYP2C9.”